Seventeen middle-aged males with sustained essential hypertension (WHO stage II) and
diastolic blood pressures (BP) exceeding 100 mm Hg during a placebo run-in period …

Twenty-three middle-aged men (59+/-2 years) with sustained, essential hypertension (WHO
Stage II) and with diastolic blood pressure exceeding 100mmHg during a run-in placebo …

The antihypertensive efficacy and tolerability of the new calcium antagonist isradipine was
assessed in 86 hypertensive patients who had pretreatment diastolic blood pressures …

The efficacy and safety of once‐daily dosing of isradipine, a new calcium antagonist
vasodilator, was evaluated in a multicenter, placebo‐controlled trial in hypertensive patients …

Isradipine, a new calcium channel blocker, was given to 32 patients with mild to moderate
essential hypertension. After a run-in period of three weeks, 32 patients were randomized …

Of the calcium channel blocking drugs, only verapamil is approved in the United States for
treatment of hypertension. Isradipine is a 1, 4-dihydropyridine calcium blocker that may be …

Isradipine, a new dihydropyridine calcium antagonist with marked vascular selectivity, was
given to 17 patients (11 men and six women, average age 56±10 years) with essential …

Abstract Treatment with the new calcium antagonist isradipine significantly reduced diastolic
blood pressure to less than 90 mm Hg in 64% of fourteen blacks with mild or moderately …

In a double-blind crossover study, 16 hypertensive patients (mean age, 41 years) were
randomly assigned to receive placebo or 5 mg of an extended-release formulation of …

Isradipine is a dihydropyridine calcium antagonist used for the treatment of hypertension. It
is highly selective for vascular smooth muscle, more than cardiac muscle, and thus, lowers …